Stock DRRX DURECT CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases DURECT Corporation

Equities

DRRX

US2666055007

Market Closed - Nasdaq
Other stock markets
 01:30:00 02/07/2024 am IST 		5-day change 1st Jan Change
1.31 USD +1.55% Intraday chart for DURECT Corporation -12.08% +122.03%
21/05 DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis CI
21/05 Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
PR
Durect: Q1 Earnings Snapshot
AQ
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
PR
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update
PR
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
PR
Durect: Q4 Earnings Snapshot
AQ
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
PR
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
PR
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada
PR
DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
PR
Durect: Q3 Earnings Snapshot
AQ
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
PR
DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update
PR
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality
PR
DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
PR
DURECT Corporation Announces Presentations in Upcoming Investor Conferences
PR
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update
AQ
Durect: Q2 Earnings Snapshot
AQ
DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update
PR
DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DRRX Stock
  4. News DURECT Corporation
  5. Press Releases